HanchorBio and InxMed Sign Strategic MOU to Explore HCB101-Based Combination Therapies for Difficult-to-Treat Solid Tumors
Collaboration aims to evaluate HCB101 with InxMed’s investigational FAK inhibitor and FAP-targeted ADC to address stromal barriers, tumor fibrosis, immune exclusion, and myeloid-mediated immunosuppression
[Taipei, Shanghai, San Francisco | July 8, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (“MOU”) with InxMed (Shanghai) Co., Ltd. (“InxMed”).
Under the MOU, the two companies will leverage their respective investigational products and technology platforms to conduct preclinical and translational research exploring rational combination strategies for difficult-to-treat solid tumors.
The collaboration will focus on HCB101, HanchorBio’s clinical-stage SIRPα-Fc fusion protein targeting the CD47/SIRPα axis, in combination with InxMed’s investigational tumor microenvironment-modulating assets, including the small-molecule FAK inhibitor IN10018/ifebemtinib and the FAP-targeted ADC OMTX705. The companies aim to evaluate whether these complementary mechanisms may help address key therapeutic barriers in solid tumors, including stromal remodeling, extracellular matrix accumulation, tumor fibrosis, immune exclusion, and myeloid-mediated immune suppression.
The signing ceremony was attended by Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio, and Zaiqi Wang, M.D., Ph.D., Founder, Chairman, and CEO of InxMed, marking the beginning of a strategic research collaboration between two innovative biopharmaceutical companies focused on immuno-oncology, tumor microenvironment biology, and cancer drug resistance.
“We are pleased to establish this partnership with InxMed,” said Dr. Liu. “InxMed has built deep expertise in key pathways related to tumor microenvironment biology and cancer drug resistance, including FAK and integrin biology, which are highly complementary to HanchorBio’s immuno-oncology strategy. Through this collaboration, we aim to evaluate HCB101’s potential to block the CD47/SIRPα signaling axis and enhance macrophage-mediated recognition and phagocytosis of tumor cells, while combining it with IN10018/ifebemtinib and OMTX705 to address tumor fibrosis, stromal barriers, and immunosuppressive features of difficult-to-treat solid tumors from different mechanistic angles.”
Dr. Liu further noted that the collaboration may deepen the understanding of HCB101’s mechanism of action across diverse tumor microenvironments and provide a research foundation for potential expansion into stroma-rich, immune-excluded, or myeloid-enriched solid tumors, such as pancreatic cancer, cholangiocarcinoma, and diffuse-type gastric cancer.
“HCB101 has demonstrated encouraging potential as a macrophage-centered immunotherapy strategy across myeloid-enriched tumor settings,” said Dr. Wang. “InxMed is committed to overcoming cancer drug resistance, and our lead asset IN10018/ifebemtinib has entered late-stage clinical development, including a Phase III trial in China for platinum-resistant recurrent ovarian cancer, and has received Fast Track designation from the U.S. FDA. We believe this collaboration may create a complementary therapeutic strategy for highly fibrotic and treatment-resistant tumor microenvironments.”
Moving forward, the two companies will review preclinical and translational research findings to determine potential next steps. The collaboration is designed to generate mechanistic and translational insights into differentiated combination strategies that may address major therapeutic barriers in difficult-to-treat solid tumors.
About InxMed
Based in the United States and China, InxMed is a late clinical-stage biotechnology company focused on overcoming drug resistance in cancer therapy. Founded in 2017, the company targets tumor defense mechanisms through key signaling pathways, including focal adhesion kinase (FAK), integrin pathways, and cancer-associated fibroblasts (CAFs). Its lead program, IN10018/ifebemtinib, is in the registrational stage and has received Breakthrough Therapy Designation from China’s NMPA and Fast Track Designation from the U.S. FDA. InxMed is led by an experienced team committed to advancing innovative cancer therapies.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and address current limitations of existing immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s research collaborations, clinical development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory interactions, regulatory decisions, protocol development, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
漢康-KY與應世生物簽署戰略合作備忘錄，探索HCB101於難治實體瘤之聯合療法策略
本合作旨在評估HCB101與應世生物之臨床研究階段FAK抑制劑及FAP標靶ADC聯合應用，以探索其對腫瘤基質屏障、腫瘤纖維化、免疫排斥及髓系細胞介導免疫抑制之潛在影響
【台北、上海、舊金山｜2026年7月8日】— 漢康生技（TWSE: 7827），為一家專注於腫瘤及免疫介導疾病之次世代免疫療法全球臨床階段生物科技公司，今（8）日宣佈其子公司 FBD Biologics Limited 與應世生物科技（上海）有限公司（以下簡稱“應世生物”）簽署戰略合作備忘錄（MOU）。
根據合作備忘錄，雙方將結合各自之臨床研究階段產品與技術平台，展開臨床前及轉譯研究，以探索針對難治實體瘤之合理聯合療法策略。
本次合作將聚焦於 HCB101，漢康-KY臨床階段之 SIRPα-Fc 融合蛋白，該產品靶向 CD47/SIRPα 訊號軸；並與應世生物具調節腫瘤微環境潛力的臨床開發中資產進行聯合應用探索，包括小分子黏著斑激酶（focal adhesion kinase, FAK）抑制劑 IN10018/ifebemtinib，以及 FAP 標靶抗體藥物複合體（ADC）OMTX705。雙方旨在評估這些具互補性的作用機制是否有助於解決實體瘤中的關鍵治療障礙，包括腫瘤基質重塑、細胞外基質累積、腫瘤纖維化、免疫排斥，以及髓系細胞介導之免疫抑制。
本次簽約儀式由漢康生技創辦人、董事長暨執行長劉世高博士，以及應世生物創辦人、董事長暨執行長王在琪醫學博士共同出席，標誌著兩家創新生技公司在腫瘤免疫、腫瘤微環境生物學及癌症抗藥性領域展開戰略研究合作。
劉世高博士表示：「我們很高興與應世生物建立合作關係。應世生物長期深耕腫瘤微環境生物學及癌症抗藥性相關關鍵路徑，包括 FAK 與整合素（integrin）生物學，與漢康的腫瘤免疫策略具有高度互補性。透過本次合作，我們將評估 HCB101 阻斷 CD47/SIRPα 訊號軸並增強巨噬細胞對腫瘤細胞辨識與吞噬作用之潛力，同時結合 IN10018/ifebemtinib 及 OMTX705，從不同機制角度探索腫瘤纖維化、基質屏障及難治實體瘤免疫抑制特徵之治療挑戰。」
劉世高博士進一步指出，本次合作可望加深公司對 HCB101 在不同腫瘤微環境中作用機制之理解，並為未來探索基質豐富、免疫排斥或髓系細胞富集之實體瘤奠定研究基礎，例如胰臟癌、膽管癌及瀰漫型胃癌等。
王在琪醫學博士表示：「HCB101 作為以巨噬細胞為核心之免疫治療策略，已在髓系細胞富集之腫瘤環境中展現令人鼓舞的潛力。應世生物長期致力於克服癌症抗藥性，我們的主要資產 IN10018/ifebemtinib 已進入後期臨床開發階段，包括於中國大陸進行鉑類藥物抗藥性復發卵巢癌之第三期臨床試驗，並已取得美國 FDA 快速通道資格。我們相信，本次合作有機會為高度纖維化及治療抗性實體瘤之腫瘤微環境，探索具互補性的治療策略。」
展望後續，雙方將審視臨床前及轉譯研究結果，以決定潛在下一步方向。本次合作旨在產生機制性與轉譯研究洞察，以支持對差異化聯合療法策略之評估，期望有助於解決難治實體瘤中的重大治療障礙。
關於應世生物：
應世生物成立於2017年，是一家處於臨床後期階段的生物科技公司，專注於克服腫瘤治療中的耐藥問題。公司聚焦腫瘤防禦機制相關關鍵通路，包括黏著斑激酶（FAK）、整合素通路及腫瘤相關成纖維細胞（CAFs），致力於瓦解腫瘤保護性微環境並提升治療反應。其核心產品 IN10018/ifebemtinib 已進入註冊性臨床階段，並獲中國國家藥監局突破性治療品種認定及美國 FDA 快速通道資格。應世生物由具國際藥物研發、臨床開發及商業化經驗的團隊領導，持續推進具創新性的癌症治療方案。
關於漢康-KY：
英屬開曼群島商漢康生技股份有限公司（以下簡稱“漢康-KY”，股票代碼：7827）成立於2020年，由具豐富國際藥物開發與運營經驗的劉世高博士創辦。公司專注於腫瘤免疫藥物研發，透過自主建立的核心「FBDB多功能融合蛋白技術平台」開發出8+種創新蛋白生物藥，具有廣譜抗癌潛力，可抑制多種實體瘤及血液腫瘤，並持續取得多項專利。其中HCB101與HCB301已進入臨床試驗階段，而HCB101在2025年6月更完成首項國際授權，總授權金達2.02億美元。漢康-KY的策略是以多功能生物藥克服現行採取免疫療法與化療並行的高失敗率，同時藉由啟動先天性免疫和適應性免疫體系以摧毀腫瘤，致力提供高效且可負擔的新一代腫瘤免疫治療方案，解決未滿足的醫療需求。
聲明：
本新聞稿及同時發佈之相關資訊內含有預測性敘述；其內容乃根據既有之風險及可能的不確定性進行判斷及預測，包括：市場因素與其他非漢康-KY（以下簡稱本公司）所能掌控之原因。這些預測性敘述是基於現況的預測和評估，除非基於法律的要求，本公司不負日後更新之責